1. Cell Cycle/DNA Damage
  2. IRE1
  3. MKC8866


Cat. No.: HY-104040 Purity: 98.38%
Handling Instructions

MKC8866 is an IRE1 RNase inhibitor with an IC50 of less than 0.1 μM for IRE1α RNase.

For research use only. We do not sell to patients.

MKC8866 Chemical Structure

MKC8866 Chemical Structure

CAS No. : 1338934-59-0

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 605 In-stock
Estimated Time of Arrival: December 31
5 mg USD 550 In-stock
Estimated Time of Arrival: December 31
10 mg USD 850 In-stock
Estimated Time of Arrival: December 31
25 mg USD 1750 In-stock
Estimated Time of Arrival: December 31
50 mg USD 2750 In-stock
Estimated Time of Arrival: December 31
100 mg USD 3950 In-stock
Estimated Time of Arrival: December 31
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Based on 1 publication(s) in Google Scholar

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


MKC8866 is an IRE1 RNase inhibitor with an IC50 of less than 0.1 μM for IRE1α RNase.

IC50 & Target

IC50: <0.1 μM (IRE1α RNase)[1]

In Vitro

Protein folding stress in the endoplasmic reticulum of a cell initiates a signal transduction cascade termed the unfolded protein response or UPR. A key enzyme, inositol requiring enzyme 1 (IRE-1α), relieves protein folding stress by enhancing molecular chaperone activity and therefore protects cells from stress induced apoptosis. MKC8866 is useful for treating at least B cell autoimmune diseases, certain cancers, and some viral infections. MKC8866 (Compound 167) inhibits IRE-1α in the in vitro assay with an IC50 of <0.1 μM. MKC8866 (Compound 167) IRE-1α in an in vivo XBP-1 splicing assay (e.g., in myeloma cells) with an EC50<10 μM[1].

In Vivo

MKC8866 is a selective IRE1 RNase inhibitor that exhibits acceptable pharmacokinetic and toxicity profiles. To determine the efficacy of MKC8866 treatment in vivo, MDA-MB-231 tumor xenografts are established in athymic nude mice. Once tumors have reached a palpable size (225-250 mm3), animals are randomized into treatment groups and treated with vehicle alone, 300 mg/kg MKC8866 alone, 10 mg/kg Paclitaxel alone or a combination of Paclitaxel and MKC8866. Treatments in all groups are administered until tumors reach maximal size (2000 mm3) or on day 60, whichever came first. MKC8866 is well tolerated after 60 consecutive oral doses and, based on pharmacokinetic allometric scaling, systemic exposures are well above anticipated clinical therapeutic levels. Following MDA-MB-231 tumor formation, mice are treated with Paclitaxel alone (7.5 mg/kg) for days 1-10, or a combination of Paclitaxel (days 1-10) and MKC8866 (300 mg/kg, days 1-28). After withdrawal of Paclitaxel treatment on day 10, an initial reduction in tumor volume is apparent in both treatment groups. Tumor re-growth, evident after day 18 in those animals receiving no further treatment, is repressed in the treatment group still receiving MKC8866. Tumor re-growth is only apparent in this group following cessation of MKC8866 on day 28[2].

Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 16.67 mg/mL (46.13 mM; Need ultrasonic)

Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7674 mL 13.8370 mL 27.6740 mL
5 mM 0.5535 mL 2.7674 mL 5.5348 mL
10 mM 0.2767 mL 1.3837 mL 2.7674 mL
*Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 1.67 mg/mL (4.62 mM); Clear solution

  • 2.

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 1.67 mg/mL (4.62 mM); Clear solution

*All of the co-solvents are provided by MCE.
Animal Administration

For the xenograft regrowth post-Paclitaxel in vivo experiments, female athymic nude mice (Crl:NU(Ncr)-Foxn1nu) are implanted subcutaneously in the right flank. Following establishment of palpable tumors, mice are randomized into treatment groups consisting of 10 mice per group with group mean tumor volumes from 227 to 230 mm3 (considered day 1 of treatment). A 7.5 mg/mL Paclitaxel stock solution in 50% ethanol: 50% Cremophor EL is prepared and stored at room temperature protected from light prior to dosing. On each day of dosing, an aliquot of the Paclitaxel stock is diluted with 5% dextrose in water (D5W) to yield a 0.75 mg/mL Paclitaxel dosing solution in a vehicle consisting of 5% ethanol: 5% Cremophor EL: 90% D5W (Vehicle 1) which provides the 7.5 mg/kg dose in a 7.5 mL/kg dosing volume. Mice are administered 7.5 mg/kg Paclitaxel once every other day for five doses by intravenous injection. MKC8866 is administered daily for 28 days at a dose volume of 10 mL/kg from a 30 mg/mL suspension in 1% microcrystalline cellulose in a simple sugar at 300 mg/kg daily by oral gavage (Vehicle 2). Group 1 receive Paclitaxel (7.5 mg/kg) alone while Group 2 receive Paclitaxel (7.5 mg/kg) plus 300 mg/kg MKC8866[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight









Room temperature in continental US; may vary elsewhere

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number *


Organization name *

Country or Region *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.:


Cat. No.: HY-104040